Department of Nephrology, Hospital Clinico Universitario de Valladolid, 47003 Valladolid, Spain.
Department of Intensive Care Medicine, Hospital Clinico Universitario de Valladolid, 47003 Valladolid, Spain.
Int J Mol Sci. 2020 Apr 27;21(9):3086. doi: 10.3390/ijms21093086.
Risk stratification and accurate patient prognosis are pending issues in the management of patients with kidney disease. The furosemide stress test (FST) has been proposed as a low-cost, fast, safe, and easy-to-perform test to assess tubular integrity, especially when compared to novel plasma and urinary biomarkers. However, the findings regarding its clinical use published so far provide insufficient evidence to recommend the generalized application of the test in daily clinical routine. Dosage, timing, and clinical outcomes of the FST proposed thus far have been significantly different, which further accentuates the need for standardization in the application of the test in order to facilitate the comparison of results between series. This review will summarize published research regarding the usefulness of the FST in different settings, providing the reader some insights about the possible implications of FST in clinical decision-making in patients with kidney disease and the challenges that research will have to address in the near future before widely applying the FST.
风险分层和准确的患者预后是肾脏疾病患者管理中的待解决问题。呋塞米应激试验（FST）已被提出作为一种低成本、快速、安全且易于进行的测试，用于评估肾小管完整性，特别是与新型血浆和尿液生物标志物相比。然而，迄今为止发表的关于其临床应用的研究结果提供的证据不足，无法推荐该测试在日常临床常规中的广泛应用。迄今为止提出的 FST 的剂量、时间和临床结果有很大差异，这进一步强调了在该测试的应用中需要标准化，以便于在系列之间比较结果。这篇综述将总结 FST 在不同环境下的有用性的已发表研究，为读者提供一些关于 FST 在肾脏病患者临床决策中的可能影响的见解，以及在广泛应用 FST 之前研究必须解决的挑战。
